SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
SAN FRANCISCO, June 05, 2024 Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary.
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0%.
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.